CoVIg-19 Plasma Alliance to Initiate Clinical Study Evaluating Hyperimmune Therapy for COVID-19 by Summer 2020
Shots: Shots:
- Takeda- CSL and NIH’s- CoVIg-19 Plasma Alliance has expanded membership and CT collaborations with >10 plasma and non-plasma companies globally to develop a plasma-derived hyperimmune globulin therapy against COVID-19
- The news member to the program includes ADMA Biologics- BioPharma Plasma- GC Pharma- and Sanquin. All the organization will provide specialist advisory expertise- technical guidance to develop the treatments whereas NIH will conduct a study to evaluate the safety- tolerability and efficacy of the hyperimmune therapy in adult patients with COVID-19
- The alliance anticipates the initiation of the global study in the summer 2020 and will form the foundation regulatory approval of the therapy. Hyperimmune globulin therapy is a collection of convalescent plasma made by purifying antibodies from donated plasma for which Microsoft and Uber Health are providing technical support including the Alliance website and the Plasmabot for donor recruitment
Click here to read full press release/ article | Ref: Takeda | Image: Hines
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
